Загрузка...
Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa
PURPOSE: In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival (PFS) when compared with interferon alfa (IFN-α) as first-line therapy in patients with metastatic renal cell carcinoma. We investigated whether baseline quality-of-life (QOL) and...
Сохранить в:
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Clinical Oncology
2009
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2790652/ https://ncbi.nlm.nih.gov/pubmed/20856722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.0922004 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|